Mofezolac
Mofezolac, a non-steroidal anti-inflammatory drug (NSAID), is a selective, reversible and orally active COX-1 inhibitor with an IC50 of 1.44 nM. Mofezolac shows weak inhibitory activity on COX-2 (IC50 of 447 nM) . Mofezolac can relieve pain and has anti-inflammatory activities[1].
Product Specifications
CAS Number
[78967-07-4]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
COX
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/mofezolac.html
Concentration
10mM
Purity
99.34
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O)CC1=C(C2=CC=C(OC)C=C2)C(C3=CC=C(OC)C=C3)=NO1
Molecular Formula
C19H17NO5
Molecular Weight
339.34
Precautions
H302, H315, H319, H335
References & Citations
[1]K Goto, et al. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Prostaglandins Other Lipid Mediat. 1998 Jul;56 (4) :245-54.|[2]Maria Laura Pati, et al. Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability. Eur J Med Chem. 2019 Feb 15;164:59-76.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
COX-1; COX-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15291341 1 Vial
Lentiviral mouse Nop14 shRNA (UAS) - Lentiviral mouse Nop14 shRNA (UAS) (25)
Ask
View Details 